Clinical Data Novo says high-dose Wegovy can cause 28% weight loss PharmaphorumNovo Nordisk has built the case for migration to its 'triple-dose' version of injectable GLP-1 Wegovy with new weight-loss and body composition data.Metabolic & GLP-1Read full story pharminent May 12, 2026 (Last updated: May 12, 2026) Pharmaphorum Novo Nordisk has built the case for migration to its ‘triple-dose’ version of injectable GLP-1 Wegovy with new weight-loss and body composition data. Metabolic & GLP-1 Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: A year after Vertex’s big launch, pain drug research faces a pivotal momentNext: FDA turns to old drugs to address new diseases, persistent medical needs Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
